Skip to content

Disc Medicine IRON Return on invested capital

Return on invested capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
13%+4.2pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
26.8%+23.0pp
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-27.6%-33.2pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-38.5%-2.4pp
Beam Therapeutics logo
Beam TherapeuticsBEAM
-39.4%-8.8pp
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-118%-48.4pp

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Based on trailing twelve months.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's return on invested capital?
Disc Medicine (IRON) reported return on invested capital of -44.3% in Q1 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.